Viemed presents at LD Micro while Viemed Healthcare stock costs EUR 8.55

Published on 10/20/2026 at 13:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Viemed presents at LD Micro on October 20, 2026. Viemed Healthcare stock costs EUR 8.55, while Q2 revenue reached USD 78.10 million.

Guidance and operating mix

Viemed's LD Micro presentation was scheduled for October 20, 2026 at 12:30 p.m. PT.
Second-quarter 2026 revenue reached USD 78.10 million, while full-year revenue guidance starts at USD 314.00 million.
Viemed Healthcare stock was trading at EUR 8.55 at 1:33 p.m. CEST at Lang & Schwarz on October 20, 2026.

VMD, CA92663R1055, Illustration mit AI erstellt.

Viemed Healthcare, Inc. (ISIN CA92663R1055) was trading at EUR 8.55 at Lang & Schwarz on October 20, 2026 at 1:33 p.m. CEST. The company was scheduled to present at the LD Micro Main Event at 12:30 p.m. PT, according to Yahoo Finance.

Three dates frame the story

On March 4, 2026, Viemed disclosed a buyback authorization covering 1,930,131 shares, according to Marketscreener. On August 3, 2026, the company reported second-quarter revenue of USD 78.10 million and diluted earnings per share of USD 0.07. On October 20, 2026, management was due to address investors at LD Micro.

The second-quarter figures show why the presentation matters beyond a routine calendar entry. Revenue reached USD 78.10 million in the quarter ended June 30, 2026, and net income attributable to Viemed was USD 2.80 million, according to the Yahoo Finance transcript.

What does the margin shift mean?

Viemed's adjusted EBITDA margin was 17.60 percent in the second quarter of 2026, versus 22.70 percent a year earlier. Management raised the low end of full-year revenue guidance to USD 314.00 million from USD 312.00 million, while lowering adjusted EBITDA guidance to USD 64.00 million-USD 68.00 million from USD 65.00 million-USD 69.00 million, according to Yahoo Finance. The combination points to faster expansion in newer service lines alongside near-term profitability pressure.

Next reporting date is November 4

Clearthesis lists November 4, 2026 as the expected date for Viemed's third-quarter 2026 results. The next scheduled investor event is therefore followed by a results date that may test the revised guidance ranges.

Stock valuation stays data dependent

Viemed's market capitalization was USD 365.3 million as of October 19, 2026, while its Nasdaq 52-week range was USD 6.05 to USD 12.61. The company says its common shares trade on the Nasdaq Capital Market under VMD, and its investor calendar identifies the second-quarter conference call on August 4, 2026.

Viemed Healthcare stock was trading at EUR 8.55 at Lang & Schwarz on October 20, 2026 at 1:33 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Viemed Healthcare stock.